Therapeutic strategies targeting the LPS signaling and cytokines

Pathophysiology

Volumn 16, Issue 4, 2009, Pages 291-296

  Wang, Hua Dong ^a   Lu, Da Xiang ^a   Qi, Ren Bin ^a  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

Author keywords

Berberine; Cytokines; Glycine; Immunomodulation; Lipopolysaccharide; Sepsis

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; BACTERIUM LIPOPOLYSACCHARIDE; BERBERINE; CYTOKINE; ERITORAN; GLYCINE; GLYCINE RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; YOHIMBINE;

BACTEREMIA; CELL PROTECTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; ENDOTOXEMIA; HEART MUSCLE CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SEPSIS; SEPTIC SHOCK; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 69249209836     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2009.02.006     Document Type: Review

References (51)

1. Andreu Ballester J.C., Ballester F., González Sánchez A., Almela Quilis A., Colomer Rubio E., and Peñarroja Otero C. Epidemiology of sepsis in the Valencian Community (Spain), 1995-2004. Infect. Control Hosp. Epidemiol. 29 (2008) 630-634
2. Padkin A., Goldfrad C., Brady A.R., Young D., Black N., and Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit. Care Med. 31 (2003) 2332-2338
3. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29 (2001) 1303-1310
4. Braude A.I., Jones J.L., and Douglas H. The behavior of Escherichia coli endotoxin (somatic antigen) during infectious arthritis. J. Immunol. 90 (1963) 297-311
5. Marshall J.C., Foster D., Vincent J.L., Cook D.J., Cohen J., Dellinger R.P., Opal S., Abraham E., Brett S.J., Smith T., Mehta S., Derzko A., Romaschin A., and MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J. Infect. Dis. 190 (2004) 527-534
6. Lepper P.M., Held T.K., Schneider E.M., Bölke E., Gerlach H., and Trautmann M. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med. 28 (2002) 824-833
7. Andreasen A.S., Krabbe K.S., Krogh-Madsen R., Taudorf S., Pedersen B.K., and Møller K. Human endotoxemia as a model of systemic inflammation. Curr. Med. Chem. 15 (2008) 1697-1705
8. Poli-de-Figueiredo L.F., Garrido A.G., Nakagawa N., and Sannomiya P. Experimental models of sepsis and their clinical relevance. Shock August 8 (2008) [Epub ahead of print PMID: 18704008]
9. Nahra R., and Dellinger R.P. Targeting the lipopolysaccharides: still a matter of debate?. Curr. Opin. Anaesthesiol. 21 (2008) 98-104
10. Opal S.M. The host response to endotoxin, antilipopolysaccharide strategies, and the management of severe sepsis. Int. J. Med. Microbiol. 297 (2007) 365-377
11. Lu Y.C., Yeh W.C., and Ohashi P.S. LPS/TLR4 signal transduction pathway. Cytokine 42 (2008) 145-151
12. Karima R., Matsumoto S., Higashi H., and Matsushima K. The molecular pathogenesis of endotoxic shock and organ failure. Mol. Med. Today 5 (1999) 123-132
13. Leon C.G., Tory R., Jia J., Sivak O., and Wasan K.M. Discovery and development of toll-like receptor 4 (TLR4) antagonists: a new paradigm for treating sepsis and other diseases. Pharm. Res. 25 (2008) 1751-1761
14. Mullarkey M., Rose J.R., Bristol J., Kawata T., Kimura A., Kobayashi S., Przetak M., Chow J., Gusovsky F., Christ W.J., and Rossignol D.P. Inhibition of endotoxin response by E5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304 (2003) 1093-1102
15. Lynn M., Rossignol D.P., Wheeler J.L., Kao R.J., Perdomo C.A., Noveck R., Vargas R., D'Angelo T., Gotzkowsky S., and McMahon F.G. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J. Infect. Dis. 187 (2003) 631-639
16. Solomon S.B., Cui X., Gerstenberger E., Danner R.L., Fitz Y., Banks S.M., Natanson C., and Eichacker P.Q. Effective dosing of lipid A analogue E5564 in rats depends on the timing of treatment and the route of Escherichia coli infection. J. Infect. Dis. 193 (2006) 634-644
17. Figueiredo M.D., Moore J.N., Vandenplas M.L., Sun W.C., and Murray T.F. Effects of the second-generation synthetic lipid A analogue E5564 on responses to endotoxin in equine whole blood and monocytes. Am. J. Vet. Res. 69 (2008) 796-803
18. Bennett-Guerrero E., Grocott H.P., Levy J.H., Stierer K.A., Hogue C.W., Cheung A.T., Newman M.F., Carter A.A., Rossignol D.P., and Collard C.D. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 104 (2007) 378-383
19. Ishii K.J., Uematsu S., and Akira S. 'Toll' gates for future immunotherapy. Curr. Pharm. Des. 12 (2006) 4135-4142
20. Tracey K.J., and Cerami A. Tumor necrosis factor: an updated review of its biology. Crit. Care Med. 21 (1993) S415-S422
21. Tracey K.J., Lowry S.F., Fahey T.J., Albert J.D., Fong Y., Hesse D., Beutler B., Manogue K.R., Calvano S., Wei H., Cerami A., and Shires G.T. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg. Gynecol. Obstet. 164 (1987) 415-422
22. Christman J.W., Holden E.P., and Blackwell T.S. Strategies for blocking the systemic effects of cytokines in the sepsis syndrome. Crit. Care. Med. 23 (1995) 955-963
23. Lorente J.A., and Marshall J.C. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 24 (2005) 107-119
24. Cao W.J., Wang H.D., Lu D.X., Wang Y.P., et al. Mechanisms for a decrease in mortality of LPS-challenged mice by rhynchophylline. Chin. J. Pathophysiol. 24 (2008) 1148-1154
25. Lu D.X., Li C.J., Fu Y.M., and Wang H.D. Inhibitory effect of glycine upon endotoxin pyrogenicity. Chin. J. Pathophysiol. 12 (1996) 235-238
26. Ikejima K., Iimuro Y., Forman D.T., and Thurman R.G. A diet containing glycine improves survival in endotoxin shock in the rat. Am. J. Physiol. 271 (1996) G97-G103
27. Bruck R., Wardi J., Aeed H., Avni Y., Shirin H., Avinoach I., Shahmurov M., and Hershkoviz R. Glycine modulates cytokine secretion, inhibits hepatic damage and improves survival in a model of endotoxemia in mice. Liver Int. 23 (2003) 276-282
28. Ding Y., Lu D.X., Sun W., Zhang S.M., and Li C.J. Observation on the effect of Gly on the TNF and IL-1 production of monocytes stimulated by ET. Chin. Pharmacol. Bull. 15 (1999) 184-185
29. Spittler A., Reissner C.M., Oehler R., Gornikiewicz A., Gruenberger T., Manhart N., Brodowicz T., Mittlboeck M., Boltz-Nitulescu G., and Roth E. Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression. FASEB. J. 13 (1999) 563-571
30. Qi R.B., Lu D.X., and Wang H.D. Effect of glycine on endotoxin induce myocardial cell injury of isolated rat heart. Chin. Pharmacological. Bull. 21 (2005) 738-741
31. Sun W., Lu D.X., Ding Y., and Li C.J. Influence of different pH and sealing of its amino terminal on the anti-endotoxin effect of glycine. Chin. J. Pathophysiol. 15 (1999) 100-112
32. Shan Y., Lu D.X., Wang H.D., Qi R.B., Fu Y.M., Li X.J., and Li C.J. Influence of glycine on LBP mRNA expression induced by LPS in the liver of rats. Chin. J. Pathophysiol. 19 (2003) 920-922
33. Xu F.L., You H.B., Li X.H., Chen X.F., Liu Z.J., and Gong J.P. Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells. Am. J. Surg. 196 (2008) 139-148
34. Zhong Z., Wheeler M.D., Li X., Froh M., Schemmer P., Yin M., Bunzendaul H., Bradford B., and Lemasters J.J. L-Glycine: a novel antiinflammatory, immunomodulatory, and cytoprotective agent. Curr. Opin. Clin. Nutr. Metab. Care 6 (2003) 229-240
35. Wheeler M., Stachlewitz R.F., Yamashina S., Ikejima K., Morrow A.L., and Thurman R.G. Glycine-gated chloride channels in neutrophils attenuate calcium influx and superoxide production. FASEB. J. 4 (2000) 476-484
36. Froh M., Thurman R.G., and Wheeler M.D. Molecular evidence for a glycine-gated chloride channel in macrophages and leukocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 283 (2002) G856-G863
37. Wheeler M.D., and Thurman R.G. Production of superoxide and TNF-alpha from alveolar macrophages is blunted by glycine. Am. J. Physiol. 277 (1999) L952-L959
38. Yang S., Koo D.J., Chaudry I.H., and Wang P. Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality. Crit. Care Med. 29 (2001) 1201-1206
39. Croner R.S., Kulu Y., Hoerer E., Peters V., Schmidt-Mader B., Schemmer P., Herfarth C., and Klar E. Intravenous glycine after cecal ligation and puncture has no effect on impaired hepatic microperfusion, leukocyte adhesion, and mortality in septic rats. Microvasc. Res. 69 (2005) 71-78
40. Fukuda K., Hibiya Y., and Mutoh M. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. J. Ethnopharmacol. 66 (1999) 227-233
41. Yang J., Wang H.D., and Lu D.X. Effects of neutral sulfate berberine on LPS-induced cardiomyocyte TNF-alpha secretion, abnormal calcium cycling, and cardiac dysfunction in rats. Acta Pharmacol. Sin. 27 (2006) 173-178
42. Li F., Wang H.D., Lu D.X., Wang Y.P., Qi R.B., Fu Y.M., and Li C.J. Neutral sulfate berberine modulates cytokine secretion and increases survival in endotoxemic mice. Acta Pharmacol. Sin. 27 (2006) 1199-1205
43. Kuo C.L., Chi C.W., and Liu T.Y. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203 (2004) 127-137
44. Zhang H.Q., Wang H.D., and Lu D.X. Berberine inhibits cytosolic phospholipase A2 and protects against LPS-induced lung injury and lethality independent of the alpha2-adrenergic receptor in mice. Shock 29 (2008) 617-622
45. Kang B.Y., Chung S.W., Cho D., and Kim T.S. Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid. Biochem. Pharmacol. 63 (2002) 1901-1910
46. Kim T.S., Kang B.Y., Cho D., and Kim S.H. Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response. Immunology 109 (2003) 407-414
47. Waterer G.W. High-mobility group box 1 (HMGB1) as a potential therapeutic target in sepsis-more questions than answers. Crit. Care Med. 35 (2007) 1205-1206
48. Schefold J.C., Hasper D., Volk H.D., and Reinke P. Sepsis: time has come to focus on the later stages. Med. Hypotheses 71 (2008) 203-208
49. Wang T.S., and Deng J.C. Molecular and cellular aspects of sepsis-induced immunosuppression. J. Mol. Med. 86 (2008) 495-506
50. Presneill J.J., Harris T., Stewart A.G., Cade J.F., and Wilson J.W. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am. J. Respir. Crit. Care Med. 166 (2002) 138-143
51. Qi R.B., Zhang J.Y., Lu D.X., Wang H.D., Wang H.H., and Li C.J. Glycine receptors contribute to cytoprotection of glycine in myocardial cells. Chin. Med. J. (Engl.) 120 (2007) 915-921